Altimmune ( (ALT) ) has released its Q3 earnings. Here is a breakdown of the information Altimmune presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for liver and cardiometabolic diseases. The company’s lead product candidate is pemvidutide, a dual receptor agonist aimed at treating conditions such as metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD).
In its latest earnings report, Altimmune announced significant advancements in its clinical programs and financial standing for the third quarter of 2025. The company is preparing for an End-of-Phase-2 meeting with the FDA for its MASH program and expects to release 48-week data from its Phase 2b IMPACT trial by the end of the year. Additionally, Altimmune has strengthened its executive team with key appointments and increased its cash reserves to $211 million as of September 30, 2025.
Key financial metrics from the quarter include a net loss of $19 million, or $0.21 per share, which is an improvement from the $22.8 million net loss reported in the same period last year. Research and development expenses decreased to $15 million, reflecting a reduction in CRO development costs, while general and administrative expenses rose slightly to $5.9 million. The company also reported interest income of $2.4 million for the quarter.
Strategically, Altimmune has made progress in its clinical trials, with early completion of patient enrollment in the RECLAIM trial for AUD and the initiation of the RESTORE trial for ALD. The company also amended its debt facility with Hercules Capital, increasing its size and extending the interest-only period, which further strengthens its financial position.
Looking ahead, Altimmune is poised for continued growth as it advances its clinical programs and seeks regulatory alignment for its Phase 3 MASH trial. The company’s focus on innovative treatments for liver and cardiometabolic diseases positions it well for future developments in these high-need areas.